SML0178

ARL-17477 dihydrochloride hydrate

≥98% (HPLC)

• 別名: N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate
• 実験式（ヒル表記法）: C₂₀H₂₀ClN₃S·2HCl · xH₂O
• CAS番号: 866914-87-6
• 分子量: 442.83 (anhydrous basis)
• MDL番号: MFCD21608518
• UNSPSCコード: 12352202
• PubChem Substance ID: 329825207
• NACRES: NA.77

特性

• アッセイ: ≥98% (HPLC)
• 形状: powder
• 保管条件: desiccated
• 色: white to beige
• 溶解性: H₂O: ≥5 mg/mL
• オーガナイザー: AstraZeneca
• 保管温度: 2-8°C
• SMILES記法: O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
• InChI: 1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
• InChI Key: QOPATWWWZNTSQF-UHFFFAOYSA-N

詳細

アプリケーション

ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.

生物化学的／生理学的作用

ARL-17477 is an nNOS specific inhibitor. The IC₅₀ against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.

特徴および利点

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全性情報

• ピクトグラム: GHS07
• シグナルワード: Warning
• 危険有害性情報: H302,H319
• 注意書き: P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501
• 危険有害性の分類: Acute Tox. 4 Oral - Eye Irrit. 2
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable